Lucid Group’s Post

View organization page for Lucid Group, graphic

13,770 followers

As a result of FDA guidance released earlier this month, we are re-sharing "Decentralised Clinical Trials: Achieving our Ambition?", first published by our #Synetic colleagues in 2023.    "This remains an incredibly challenging space for biopharmaceutical companies. There is a stakeholder consensus that decentralised elements will benefit many patients. However, regulatory, legal, logistical and ethical considerations have resulted in a more cautious adoption. This paper discusses the challenges and proposes critical success factors for conducting decentralised elements within the clinical trial setting." Steve Gunnigle (Lead Author and Vice President, Consulting at #Synetic)   Matthew McLoughlin Mary Alice Dwyer Neil Croft Synetic Life Sciences   #ClinicalDevelopment #ClinicalOperations #Biopharmaceutical #DecentralisedClinicalTrials #DecentralizedClinicalTrials #DCT #FDA

To view or add a comment, sign in

Explore topics